Mesfer Al Shahrani

Dr. Mesfer Al Shahrani


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Mohit Mahesh AngolkarMohit Mahesh Angolkar
Mohit Mahesh Angolkar
SPSharanya Paramshetti
Sharanya Paramshetti
RGReem M. Gahtani
Reem M. Gahtani
MSMesfer Al Shahrani
Mesfer Al Shahrani
UHUmme Hani
Umme Hani
GRGundawar Ravi
Gundawar Ravi

16 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TATahani M. Almeleebia
Tahani M. Almeleebia
MSMesfer Al Shahrani
Mesfer Al Shahrani
MAMohammad alshahrani
Mohammad alshahrani
IAIrfan Ahmad
Irfan Ahmad
AAAbdullah Alkahtani
Abdullah Alkahtani
SISana Iram
Sana Iram
Mycobacterium tuberculosis (Mtb) is a deadly tuberculosis (TB)-causing pathogen. The proteasome is vital to the survival of Mtb and is therefore validated as a potential target for anti-TB therapy. Mtb resistance to existing antibacterial agents has enhanced drastically, becoming a worldwide health issue. Therefore, new potential therapeutic agents need to be developed that can overcome the complications of TB. With this purpose, in the present study, 224,205 natural compounds from the ZINC database have been screened against the catalytic site of Mtb proteasome by the computational approach. The best scoring hits, ZINC3875469, ZINC4076131, and ZINC1883067, demonstrated robust interaction with Mtb proteasome with binding energy values of −7.19, −7.95, and −7.21 kcal/mol for the monomer (K-chain) and −8.05, −9.10, and −7.07 kcal/mol for the dimer (both K and L chains) of the beta subunit, which is relatively higher than that of reference compound HT1171 (−5.83 kcal/mol (monomer) and −5.97 kcal/mol (dimer)). In-depth molecular docking of top-scoring compounds with Mtb proteasome reveals that amino acid residues Thr1, Arg19, Ser20, Thr21, Gln22, Gly23, Asn24, Lys33, Gly47, Asp124, Ala126, Trp129, and Ala180 are crucial in binding. Furthermore, a molecular dynamics study showed steady-state interaction of hit compounds with Mtb proteasome. Computational prediction of physicochemical property assessment showed that these hits are non-toxic and possess good drug-likeness properties. This study proposed that these compounds could be utilized as potential inhibitors of Mtb proteasome to combat TB infection. However, there is a need for further bench work experiments for their validation as inhibitors of Mtb proteasome.

1 January 2021 in Oncology Research
Verified
Journal Article
Open access
PDF file
MSMesfer Al Shahrani
Mesfer Al Shahrani
PRPrasanna Rajagopalan
Prasanna Rajagopalan
MAMohammad Abohassan
Mohammad Abohassan
MAMohammad Alshahrani
Mohammad Alshahrani
YAYasser Alraey
Yasser Alraey
KDKhlood Dagreery
Khlood Dagreery
Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6- methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (1 H-NMR), 13C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were differentiated using phorbol 12-myristate 13-acetate. ERα inhibition was assessed using ELISA. The MTT assay assessed cell viability. Flow cytometry was performed for cell cycle, apoptosis, and p-Akt analyses. Chemical analysis identified the compound as 3-(4-isopropyl) benzylidene-8-ethoxy,6-methyl, chroman-4-one, which showed high binding efficacy toward ER, with a ΔGbinding score of −7.4 kcal/mol. SBL-060 inhibited ERα, exhibiting IC50 values of 448 and 374.3 nM in THP-1 and HL-60 cells, respectively. Regarding inhibited cell proliferation, GI50 values of SBL-060 were 244.1 and 189.9 nM for THP-1 and HL-60 cells, respectively. In addition, a dose-dependent increase in sub G0/G1 phase cell cycle arrest and total apoptosis was observed after treatment with SBL-060 in both cell types. SBL-060 also dose-dependently increased the p-Akt-positive populations in both THP-1 and HL-60 cells. Our results indicate that SBL-060 has excellent efficacy against differentiated AML cell types by inhibiting ER and Akt kinase, warranting further preclinical evaluations.

23 April 2022 in Saudi Journal of Biological Sciences
Verified
Journal Article
Open access
MSMesfer Al Shahrani
Mesfer Al Shahrani
PRPrasanna Rajagopalan
Prasanna Rajagopalan
MAMohammad Abohassan
Mohammad Abohassan
MAMohammad Alshahrani
Mohammad Alshahrani
YAYasser Alraey
Yasser Alraey
Predicting novel dual inhibitors to combat adverse effects such as the development of resistance to vemurafenib in melanoma treatment due to the reactivation of MAPK and PI3K/AKT signaling pathways is studied to help in reversal of cancer symptoms. Reversal of cancer symptoms in melanoma associated with vemurafenib resistance is driven by reactivation of MAPK and PI3K/Akt signaling pathways. Novel dual inhibitors targeting these proteins would be beneficial to combat resistance. High-throughput virtual screening of the ChemBridge library against B-RAFV600E and Akt was performed using an automated protocol with the AutoDock VINA program. Luminescence and time-resolved fluorescence kits were used to measure enzyme activities. The MTT assay was used to determine proliferation in normal and vemurafenib-resistant A375 cells. Flow cytometry was used to examine apoptosis, cell cycle, and phosphorylation of ERK/Akt signaling pathway. High-throughput screening from the ChemBridge library identified 15 compounds with high binding energy towards B-RAFV600E; among these, CB-RAF600E-1 had the highest ΔGbinding score −11.9 kcal/mol. The compound also had a high affinity towards Akt, with a ΔGbinding score of −11.5 kcal/mol. CB-RAF600E-1 dose-dependently inhibited both B-RAFV600E and Akt with IC50 values of 635 nM and 154.3 nM, respectively. The compound effectively controlled the proliferations of normal and vemurafenib-resistant A375 cells, with GI50 values of 222.3 nM and 230.5 nM, respectively. A dose-dependent increase in the sub G0/G1 phase of the cell cycle and total apoptosis was observed following compound treatment in both normal and vemurafenib-resistant melanoma cells. Treatment with CB-RAF600E-1 decreased the pERK/pAkt dual-positive populations in normal and vemurafenib-resistant A375 cells. CB-RAF600E-1, identified as a novel dual inhibitor effective against normal and vemurafenib-resistant melanoma cells, requires further attention for development as an effective chemotherapeutic agent for melanoma management.

30 June 2023 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
ADAyed A. Dera
Ayed A. Dera
BABashayr Algamdi
Bashayr Algamdi
IAIrfan Ahmad
Irfan Ahmad
MSMesfer Al Shahrani
Mesfer Al Shahrani
YAYasser Alraey
Yasser Alraey
SASyed Parween Mazher Ali
Syed Parween Mazher Ali
In the current scenario, the importance of cardiac biomarkers in diagnosing, assessing, and managing people with cardiovascular discomfort is required. This cross-sectional study examined the relationship between serum leptin and resistin levels among obese people with acute myocardial infarction (AMI) with varying body mass index (BMI). The cardio and diabetic biomarkers among the 77 Saudi patients with hypoxia who lived in the Asir region were analyzed in the study. The patients were categorized into three groups, namely, group 1 (control), group 2 (AMI with normal BMI), and group 3 (AMI with varying BMI). Our results showed a positive correlation between serum glucose, HbA1C, triglycerides, Troponin-I (cTnI), creatine kinase MB (CK-MB), leptin, and resistin in patients with AMI. We also observed significantly lower HbA1C, cholesterol, and insulin values in groups 2 and 3. A statistical difference between the groups with and without AMI and between the genders was noticed. BMI with leptin showed a positive connection in group 3 but no association was observed for groups 1 and 2. A stronger relationship between BMI and leptin levels in men in Group 3 than in women was observed. In all three groups, resistin levels did not correlate with BMI. Thus, circulating leptin concentrations do not significant impact AMI compared to participants with and without AMI. However, resistin levels were considerably higher in obese individuals with AMI. Therefore, we suggest that resistin can be used as a pro-inflammatory marker to detect AMI disorder with varying BMI and as a prognostic marker associated with AMI.

6 December 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
ADAyed A. Dera
Ayed A. Dera
MSMesfer Al Shahrani
Mesfer Al Shahrani
GZGAFFAR ZAMAN
GAFFAR ZAMAN
AAAhmad Mohammed Asiri
Ahmad Mohammed Asiri
AAAbdullah Alasmari
Abdullah Alasmari
AAAbdulrhman Khalofa Alasmari
Abdulrhman Khalofa Alasmari
A glycogen storage disease (GSD) is a metabolic disorder caused by a deficiency of an enzyme or transport protein affecting glycogen synthesis, glycogen breakdown, or glucose breakdown, typically in muscles and/or liver cells. Several enzymes are required for the processes of glycogenesis and glycogenolysis. Glycogen storage diseases happen when a person doesn't have one or more of these enzymes. GSD in almost all cases is genetic (In exceptional cases, it can be environmental, like GSD in livestock). Genetic GSD results mainly from inborn error in carbohydrate metabolism, where genetically faulty or malfunctioning enzymes or transport proteins are involved. It has many different types and diagnoses depending upon history, physical examinations and more specifically, blood tests and biopsies for related disturbances and genetic testing wherever mutations are being suspected. It is very important to distinguish the different types so that the patient receives the correct treatment. To even summarize the treatment modalities of the different sub-groups was beyond the scope of this study. We hope that it will elucidate better approaches and techniques amongst collaborative team members from the medical fraternity.